A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD
Introduction
The Global Initiative for Obstructive Lung Disease (GOLD) guidelines, which were updated in July 2003, highlighted the role of long-acting bronchodilators in symptomatic management of all stages of chronic obstructive pulmonary disease (COPD) [1]. They also warranted that regular treatment with inhaled corticosteroids is only appropriate for symptomatic COPD patients with an FEV1<50% predicted (Stage III: severe COPD; and Stage IV: very severe COPD) and repeated exacerbations requiring treatment with antibiotics or oral corticosteroids.
Afterwards, Tashkin and Cooper [2] emphasized the advantage of tiotropium on long-acting β2-agonists, and suggested a single long-acting bronchodilator plus an as-needed, short-acting agent in moderate disease (stage II of the GOLD classification [1]), the combination of long-acting anticholinergic and long-acting β2-adrenergic therapy with progression of disease severity, with or without the addition of inhaled corticosteroids for patients with frequent exacerbations or inadequate symptom control despite optimal treatment with bronchodilators alone (stage III/IV). In effect, some papers have documented the advantage for COPD patients in combining long-acting anticholinergic and long-acting β2-adrenergic agents [3], [4], [5], [6]. Other papers [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15] have clearly shown that both long-acting β2-agonists and inhaled corticosteroids have an important role in COPD, which increases when the two drugs are combined in the same therapeutic regimen.
Unfortunately, although tiotropium has entered the market with a wide and solid documentation of its efficacy in stable COPD, the interesting comparison of the combination inhaler with a long acting β2-agonist and an inhaled corticosteroid versus tiotropium has not yet been undertaken [16]. Moreover, we do not know if there is a real advantage in administering a long-acting β2-agonist/inhaled corticosteroid combination together with tiotropium for treating severe-to-very severe COPD.
For this reason, the current study was designed to compare the efficacy and safety of 12 weeks’ therapy with fluticasone propionate/salmeterol combination (FSC) and tiotropium with that of individual treatments alone in patients with severe-to-very severe stable COPD.
Section snippets
Patients and methods
Ninety patients with well-controlled COPD were enrolled. All were 50 years of age or older, and were current or former smokers with a 20 pack-year or more history. Inclusion criteria required a baseline FEV1 of less than 50% of predicted, and a post-bronchodilator FEV1/FVC<70% following salbutamol 400 μg according with the GOLD criteria of severity [1]. Exclusion criteria were as follows: current evidence of asthma as primary diagnosis; unstable respiratory disease requiring oral/parenteral
Results
Eighty-one patients completed the 3-month treatment period: 26 patients receiving FSC, 26 patients receiving tiotropium, and 29 patients receiving FSC+tiotropium. Patients were withdrawn for COPD exacerbation resulting in hospitalization or even treatment with an oral corticosteroid. There was no significant difference among the baseline spirometric values of the three treatment groups (FEV1, )).
Significant improvements in trough FEV1 above baseline with all treatments
Discussion
In this study, the improvement in pulmonary function, expressed as a change in FEV1, did not differ between tiotropium and FSC, but the simultaneous administration of the two treatments provided greater improvements in through FEV1 compared to therapy with the other two therapeutic regimens. This is an intriguing finding, but our data do not allow to establish if the improvements in lung function caused by combining fluticasone propionate/salmeterol and tiotropium in severe-to-very severe COPD
References (26)
- et al.
The role of long-acting bronchodilators in the management of stable COPD
Chest
(2004) - et al.
The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD
Pulm Pharmacol Ther
(2004) - et al.
The functional impact of adding salmeterol and tiotropium in patients with stable COPD
Respir Med
(2004) - et al.
Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients
Respir Med
(2005) - et al.
Additive effects of salmeterol and fluticasone or theophylline in COPD
Chest
(2000) - et al.
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial
Lancet
(2003) - et al.
Salmeterol & fluticasone 50 μg/250 μg bid in combination provides a better long-term control than salmeterol 50 μg bid alone and placebo in COPD patients already treated with theophylline
Pulm Pharmacol Ther
(2003) - et al.
The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD
Chest
(2003) - et al.
Salmeterol/fluticasone propionate in a single inhaler device versus theophylline+fluticasone propionate in patients with COPD
Pulm Pharmacol Ther
(2004) - et al.
Long-acting bronchodilators are the first-choice option for the treatment of stable COPD
Chest
(2004)